Prescription medicine
Rifampin First approved as Rifadin
Rifampin (Rifadin) is a prescription medicine with an FDA approval on record since 1971. FDA's NDC Directory lists it from 13 generic labelers, and pharmacies paid $0.679 per rifampin 300 mg capsule in the October 7, 2026 NADAC survey.
- Generic listed
- In shortage
Check it at the source: the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.); the NDA 50420 record on Drugs@FDA; every rifampin label on DailyMed.
Highlights of the record
FDA label of February 11, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageIn the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type.
Forms and strengths
- 150 mg
- 300 mg
- 600 mg
- 600 mg/10ml
Capsule; injection (powder) (lyophilized) for solution.
On the market
- Earliest approval on file
- May 21, 1971 Rifadin, Sanofi Aventis Us; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 12 first May 28, 1997; 9 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 13 of which 13 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.679 per capsule Rifampin 300 mg capsule
- Shortage (FDA)
- 7 of 13 presentations limited or unavailable updated October 6, 2026
- Recalls by its makers (FDA)
- 14 since 2014 0 Class I among all firms' recalls; latest March 21, 2024; 7 more by firms not listed as its makers
- FAERS reports
- 14,511 through July 30, 2026
What is rifampin used for?
From the label: indications and usageIn the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified. […]
FDA pharmacologic class: Rifamycin Antibacterial.
Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed
Is there a generic for rifampin (Rifadin)?
The FDA approved the first generic rifampin on May 28, 1997. 12 generic applications are approved; 9 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists rifampin from 13 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1971 earliest approval on file
- 1997 first generic approved
- 2021 to now in shortage
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for rifampin (Rifadin)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.679 per Rifampin 300 mg capsule, down 4% from $0.704 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Rifampin 300 mg capsule (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Rifampin 150 mg capsule | Generic | $0.898 per capsule | $26.93 | +42% |
| Rifampin 300 mg capsule | Generic | $0.679 per capsule | $20.37 | -4% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is rifampin in shortage?
The FDA Drug Shortage Database lists 7 of 13 rifampin presentations as limited or unavailable (updated October 6, 2026); the first entry was posted on February 17, 2021. 5 more presentations are on the list as available.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Rifadin, Injection, 600 mg (NDC 0068-0597-01) | Sanofi-Aventis U.S. LLC | Current | September 18, 2026 |
| Rifampin, Capsule, 150 mg (NDC 42806-801-01) | Epic Pharma, LLC | Current | October 5, 2026 |
| Rifampin, Capsule, 150 mg (NDC 42806-801-30) | Epic Pharma, LLC | Current | October 5, 2026 |
| Rifampin, Capsule, 150 mg (NDC 68180-658-06) | Lupin Pharmaceuticals, Inc. | Current | September 1, 2026 |
| Rifampin, Capsule, 300 mg (NDC 42806-799-01) | Epic Pharma, LLC | Current | October 5, 2026 |
| Rifampin, Capsule, 300 mg (NDC 42806-799-05) | Epic Pharma, LLC | Current | October 5, 2026 |
| Rifampin, Capsule, 300 mg (NDC 42806-799-30) | Epic Pharma, LLC | Current | October 5, 2026 |
| Rifampin, Capsule, 300 mg (NDC 42806-799-60) | Epic Pharma, LLC | Current | October 5, 2026 |
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
Has rifampin been recalled?
The FDA's Enforcement Report lists 21 recalls naming rifampin since 2014: 0 Class I (the most serious), 19 Class II, 2 Class III; 4 still ongoing. 7 of them are by firms that FDA's NDC Directory does not list as a maker of rifampin and that hold no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| March 21, 2024 | Class II | Lupin Pharmaceuticals Inc. | Subpotent Drug |
| January 11, 2024 | Class II | Amerisource Health Services LLC | Failed Impurities/Degradation Specification. |
| January 5, 2024 | Class II | Lupin Pharmaceuticals Inc. | Subpotent Drug and Failed Impurities/Degradation Specifications |
| April 26, 2023 | Class II | Akorn, Inc. not a listed maker | CGMP Deviations: Firm went out of business and could no longer continue stability studies. |
| December 20, 2022 | Class II | RemedyRepack Inc. | Failed Impurities/Degradation specifications |
| December 20, 2022 | Class II | Amerisource Health Services LLC | Failed Impurities/Degradations Specifications |
| December 12, 2022 | Class II | Lupin Pharmaceuticals Inc. | Failed Impurities/Degradation Specifications: Failure observed in related substance testing during long term stability study. |
| October 6, 2022 | Class II | Golden State Medical Supply Inc. | Failed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-Nitrosopoperazine (MNP). |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the rifampin label say about other medicines?
The rifampin label names 9 other medicines in its interaction, contraindication or warning sections. The labels of 36 other medicines name rifampin. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Atazanavir | contraindications | Rifampin is contraindicated in patients who are also receiving atazanavir, darunavir, fosamprenavir, saquinavir, tipranavir, cabotegravir, fostemsavir and lenacapavir (see prescribing information for SUNLENCA) due to the potential of rifampin to substantially decrease plasma concentrations of these antiviral drugs … |
| Cabotegravir | contraindications | Rifampin is contraindicated in patients who are also receiving atazanavir, darunavir, fosamprenavir, saquinavir, tipranavir, cabotegravir, fostemsavir and lenacapavir (see prescribing information for SUNLENCA) due to the potential of rifampin to substantially decrease plasma concentrations of these antiviral drugs … |
| Cefazolin | warnings | Postmarketing reports suggest that concomitant administration of high doses of cefazolin and rifampin may prolong the prothrombin time, leading to severe vitamin K–dependent coagulation disorders that may be life-threatening or fatal. |
| Darunavir | contraindications | Rifampin is contraindicated in patients who are also receiving atazanavir, darunavir, fosamprenavir, saquinavir, tipranavir, cabotegravir, fostemsavir and lenacapavir (see prescribing information for SUNLENCA) due to the potential of rifampin to substantially decrease plasma concentrations of these antiviral drugs … |
| Fosamprenavir | contraindications | Rifampin is contraindicated in patients who are also receiving atazanavir, darunavir, fosamprenavir, saquinavir, tipranavir, cabotegravir, fostemsavir and lenacapavir (see prescribing information for SUNLENCA) due to the potential of rifampin to substantially decrease plasma concentrations of these antiviral drugs … |
| Fostemsavir | contraindications | Rifampin is contraindicated in patients who are also receiving atazanavir, darunavir, fosamprenavir, saquinavir, tipranavir, cabotegravir, fostemsavir and lenacapavir (see prescribing information for SUNLENCA) due to the potential of rifampin to substantially decrease plasma concentrations of these antiviral drugs … |
| Lenacapavir | contraindications | Rifampin is contraindicated in patients who are also receiving atazanavir, darunavir, fosamprenavir, saquinavir, tipranavir, cabotegravir, fostemsavir and lenacapavir (see prescribing information for SUNLENCA) due to the potential of rifampin to substantially decrease plasma concentrations of these antiviral drugs … |
| Lurasidone | contraindications | Rifampin is contraindicated in patients receiving lurasidone. |
| Praziquantel | contraindications | Rifampin is contraindicated in patients receiving praziquantel since therapeutically effective blood levels of praziquantel may not be achieved. |
Other labels that name rifampin
- Abiraterone
- Acalabrutinib
- Acetaminophen and benzhydrocodone
- Aficamten
- Aminophylline
- Apixaban
- Apremilast
- Aprepitant
- Aripiprazole
- Aripiprazole lauroxil
- Artemether and lumefantrine
- Atogepant
- Atorvastatin
- Atovaquone
- Atovaquone and proguanil
- Avacopan
- Axitinib
- Bedaquiline
- Bisoprolol
- Brincidofovir
- Brivaracetam
- Buprenorphine
- Buspirone
- Cabozantinib
- Canagliflozin
- Cannabidiol
- Carbamazepine
- Carvedilol
- Caspofungin
- Celecoxib
- Ceritinib
- Clopidogrel
- Cobicistat
- Cobimetinib
- Codeine
- Dabigatran
- Dapagliflozin
- Daprodustat
- Deflazacort
- Dexamethasone
- Dexlansoprazole
- Diazepam
- Diclofenac
- Divalproex
- Dolutegravir
- Donepezil and memantine
- Doravirine
- Dronedarone
- Drospirenone and ethinyl estradiol
- Drospirenone and ethinyl estradiol and levomefolate
- Edoxaban
- Efavirenz
- Elafibranor
- Elagolix
- Elbasvir and grazoprevir
- Eltrombopag
- Eluxadoline
- Ensitrelvir
- Enzalutamide
- Erlotinib
- Esomeprazole
- Estazolam
- Estradiol
- Estrogens conjugated
- Ethinyl estradiol and ferrous fumarate and norethindrone
- Etrasimod arginine
- Etravirine
- Everolimus
- Fentanyl
- Fesoterodine
- Fluconazole
- Fludrocortisone
- Fosaprepitant
- Gemfibrozil
- Glecaprevir and pibrentasvir
- Glimepiride
- Glyburide
- Guanfacine
- Hydrocodone
- Hydrocortisone
- Iptacopan
- Irinotecan
- Isavuconazonium
- Isoniazid
- Istradefylline
- Ivacaftor
- Ixazomib
- Lamotrigine
- Lansoprazole
- Leflunomide
- Lemborexant
- Letermovir
- Levonorgestrel
- Levothyroxine
- Linagliptin
- Liothyronine
- Losartan
- Macitentan
- Maribavir
- Meperidine
- Methadone
- Methylergonovine
- Methylprednisolone
- Mifepristone
- Mycophenolic acid
- Naloxegol
- Nateglinide
- Nelfinavir
- Nevirapine
- Nifedipine
- Olanzapine
- Oliceridine
- Omeprazole
- Ondansetron
- Osilodrostat
- Ospemifene
- Oxcarbazepine
- Oxycodone
- Ozanimod
- Paclitaxel
- Palbociclib
- Paliperidone
- Pioglitazone
- Pitavastatin
- Prednisolone
- Pretomanid
- Probenecid and sulopenem etzadroxil
- Propafenone
- Propranolol
- Quetiapine
- Quinidine
- Raltegravir
- Ramelteon
- Ranolazine
- Repaglinide
- Rifabutin
- Rifapentine
- Rilpivirine
- Risperidone
- Ritlecitinib
- Ritonavir
- Rivaroxaban
- Rolapitant
- Seladelpar lysine
- Selegiline
- Selexipag
- Sirolimus
- Sofosbuvir and velpatasvir and voxilaprevir
- Sorafenib
- Stiripentol
- Sufentanil
- Suvorexant
- Tacrolimus
- Tadalafil
- Tamoxifen
- Tasimelteon
- Temsirolimus
- Tenofovir alafenamide
- Terbinafine
- Teriflunomide
- Theophylline
- Thiotepa
- Ticagrelor
- Tinidazole
- Tofacitinib
- Torsemide
- Trabectedin
- Tramadol
- Treprostinil
- Triamcinolone
- Ubrogepant
- Ulipristal
- Upadacitinib
- Valproic acid
- Vemurafenib
- Verapamil
- Vilazodone
- Voriconazole
- Zaleplon
Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed
What do FAERS reports show for rifampin?
The FDA Adverse Event Reporting System holds 14,511 reports that list rifampin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1,483 are coded as a death and 5,858 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other rifamycin antibacterials
- the pharmacologic class, with prices and generics
- Rifampin side effects
- the label's list beside FAERS reports
- Rifampin shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other